{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:49:37Z","timestamp":1791920977089,"version":"4.3.4"},"reference-count":165,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.xphs.2022.06.004","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T15:31:49Z","timestamp":1654788709000},"page":"2652-2661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-3030","authenticated-orcid":false,"given":"Gokben","family":"Sahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6524-3535","authenticated-orcid":false,"given":"Ozlem","family":"Akbal-Dagistan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7948-4340","authenticated-orcid":false,"given":"Meltem","family":"Culha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5179-5865","authenticated-orcid":false,"given":"Aybige","family":"Erturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-5292","authenticated-orcid":false,"given":"Nur Sena","family":"Basarir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serap","family":"Sancar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2243-6684","authenticated-orcid":false,"given":"Ayca","family":"Yildiz-Pekoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.xphs.2022.06.004_bib0001","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: recent insights into emerging coronaviruses","volume":"14","author":"De Wit","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.xphs.2022.06.004_bib0002","unstructured":"WHO Timeline - COVID-19. January 4, 2022. Published 2020. Accessed https:\/\/www.who.int\/news-room\/detail\/27-04-2020-who-timeline\u2014covid-19"},{"key":"10.1016\/j.xphs.2022.06.004_bib0003","series-title":"Coronavirus disease (COVID-19) pandemic","author":"WHO","year":"2022"},{"issue":"4","key":"10.1016\/j.xphs.2022.06.004_bib0004","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jps.23465","article-title":"Back to the future: inhaled drug products","volume":"102","author":"Hickey","year":"2013","journal-title":"J Pharm Sci"},{"issue":"1077","key":"10.1016\/j.xphs.2022.06.004_bib0005","first-page":"1","article-title":"Inhalation delivery for the treatment and prevention of COVID-19 infection","volume":"13","author":"Eedara","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.xphs.2022.06.004_bib0006","first-page":"367","article-title":"The inhalation of drugs: Advantages and problems","volume":"50","author":"Rau","year":"2005","journal-title":"Respir Care"},{"key":"10.1016\/j.xphs.2022.06.004_bib0007","series-title":"Clinical Management of Severe Acute Respiratory Infection When COVID-19 is Suspected","author":"WHO","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0008","unstructured":"Kamps BS, Hoffman C. COVID Reference. 3. 2020, 2020. https:\/\/covidreference.com\/timeline_it"},{"key":"10.1016\/j.xphs.2022.06.004_bib0009","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3906\/sag-2004-145","article-title":"Antiviral treatment of COVID-19","volume":"50","author":"\u015eim\u015fek Yavuz","year":"2020","journal-title":"Turkish J Med Sci"},{"issue":"10","key":"10.1016\/j.xphs.2022.06.004_bib0010","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xphs.2022.06.004_bib0011","first-page":"1","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","author":"Grein","year":"2020","journal-title":"N Engl J Med. Published online"},{"issue":"0","key":"10.1016\/j.xphs.2022.06.004_bib0012","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.xphs.2022.06.004_bib0013","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19 \u2014 Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xphs.2022.06.004_bib0014","series-title":"Gilead Announces Approval of Veklury\u00ae (remdesivir) in Japan for Patients With Severe COVID-19","author":"Gilead","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0015","series-title":"Veklury (remdesivir) EUA Letter of Approval","author":"FDA","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0016","series-title":"Frequently Asked Questions for Veklury (remdesivir)","author":"FDA","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0017","series-title":"Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19","author":"FDA","year":"2022"},{"issue":"9","key":"10.1016\/j.xphs.2022.06.004_bib0018","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.xphs.2022.06.004_bib0019","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"issue":"10259","key":"10.1016\/j.xphs.2022.06.004_bib0020","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","article-title":"Lopinavir\u2013ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"396","year":"2020","journal-title":"Lancet"},{"issue":"June","key":"10.1016\/j.xphs.2022.06.004_bib0021","article-title":"Lopinavir\/ritonavir and darunavir\/cobicistat in hospitalized COVID-19 patients: findings from the multicenter Italian CORIST study","volume":"8","author":"Di Castelnuovo","year":"2021","journal-title":"Front Med"},{"issue":"6","key":"10.1016\/j.xphs.2022.06.004_bib0022","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/14787210.2021.1848545","article-title":"Efficacy and safety of lopinavir\/ritonavir in the treatment of COVID-19: a systematic review","volume":"19","author":"Joseph","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"10.1016\/j.xphs.2022.06.004_bib0023","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jiph.2021.03.015","article-title":"Efficacy and safety of lopinavir-ritonavir in COVID-19: a systematic review of randomized controlled trials","volume":"14","author":"Patel","year":"2021","journal-title":"J Infect Public Health"},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0024","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: an update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antiviral Res"},{"issue":"2","key":"10.1016\/j.xphs.2022.06.004_bib0025","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1073\/pnas.1617020114","article-title":"Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol","volume":"114","author":"Kadam","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xphs.2022.06.004_bib0026","article-title":"Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China","author":"Wang","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0027","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","volume":"81","author":"Zhu","year":"2020","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0028","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against corona virus disease 2019: a retrospective cohort study","volume":"81","author":"Deng","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.xphs.2022.06.004_bib0029","first-page":"1","article-title":"Efficacies of lopinavir\/ritonavir and abidol in the treatment of novel coronavirus pneumonia","volume":"12","author":"Chen","year":"2020","journal-title":"Chinese J Infect Dis"},{"key":"10.1016\/j.xphs.2022.06.004_bib0030","first-page":"1","article-title":"An exploratory randomized controlled study on the efficacy and safety of lopinavir\/ritonavir or arbidol treating adult patients hospitalized with mild\/moderate COVID-19 (ELACOI)","author":"Li","year":"2020","journal-title":"medRxiv (Preprint)"},{"issue":"4","key":"10.1016\/j.xphs.2022.06.004_bib0031","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2174\/1573398X17666210129125703","article-title":"Comparison the effect of arbidol plus hydroxychloroquine vs hydroxychloroquine alone in treatment of COVID-19 disease: a randomized clinical trial","volume":"16","author":"Khodashahi","year":"2021","journal-title":"Curr Respir Med Rev"},{"issue":"July","key":"10.1016\/j.xphs.2022.06.004_bib0032","article-title":"Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial","volume":"99","author":"Alavi Darazam","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"10.1016\/j.xphs.2022.06.004_bib0033","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cmi.2020.04.026","article-title":"Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study","volume":"26","author":"Lian","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0034","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.xphs.2022.06.004_bib0035","first-page":"1","article-title":"Review of side effects and toxicity of chloroqine","author":"Weniger","year":"1979","journal-title":"World Heal Organ. Published online"},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12977-015-0178-0","article-title":"Chloroquine and beyond: Exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV\/AIDS","volume":"12","author":"Savarino","year":"2015","journal-title":"Retrovirology"},{"issue":"2","key":"10.1016\/j.xphs.2022.06.004_bib0037","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1473-3099(06)70361-9","article-title":"New insights into the antiviral effects of chloroquine","volume":"6","author":"Savarino","year":"2006","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.xphs.2022.06.004_bib0038","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/cr.2012.165","article-title":"Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model","volume":"23","author":"Yan","year":"2013","journal-title":"Cell Res"},{"issue":"69","key":"10.1016\/j.xphs.2022.06.004_bib0039","first-page":"1","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"issue":"3","key":"10.1016\/j.xphs.2022.06.004_bib0040","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"issue":"September","key":"10.1016\/j.xphs.2022.06.004_bib0041","article-title":"Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2","volume":"585","author":"Hoffmann","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.xphs.2022.06.004_bib0042","first-page":"185","article-title":"Province of Science and Technology of Guangdong, Province and Health Commission of, Guangdong Novel for Chloroquine in the Treatment of Pneumonia Coronavirus. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia","volume":"43","author":"Multicenter Collaboration Group of Department","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0043","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"issue":"4","key":"10.1016\/j.xphs.2022.06.004_bib0044","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw open"},{"issue":"1 PART 1","key":"10.1016\/j.xphs.2022.06.004_bib0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","article-title":"Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate","volume":"75","author":"McChesney","year":"1983","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.xphs.2022.06.004_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105945","article-title":"Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine","volume":"55","author":"Sahraei","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"15","key":"10.1016\/j.xphs.2022.06.004_bib0047","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.xphs.2022.06.004_bib0048","volume":"7","author":"Chen","year":"2020","journal-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial"},{"key":"10.1016\/j.xphs.2022.06.004_bib0049","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19","author":"Cavalcanti","year":"2020","journal-title":"N Engl J Med"},{"issue":"April","key":"10.1016\/j.xphs.2022.06.004_bib0050","first-page":"1","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.xphs.2022.06.004_bib0051","series-title":"No Clinical Benefit From Use of Hydroxychloroquine in Hospitalised Patients with COVID-19","year":"2022"},{"issue":"10","key":"10.1016\/j.xphs.2022.06.004_bib0052","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa446","article-title":"Treating COVID-19 with hydroxychloroquine (TEACH): a multicenter, double-blind randomized controlled trial in hospitalized patients","volume":"7","author":"Ulrich","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.xphs.2022.06.004_bib0053","article-title":"A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)","volume":"15","author":"Chen","year":"2020","journal-title":"Atkin SL, ed. PLoS One"},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0054","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41467-020-19056-6","article-title":"A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics","volume":"11","author":"Lyngbakken","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.xphs.2022.06.004_bib0055","first-page":"1","article-title":"Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect\u00a0: a critical step in treating patients with coronavirus disease 2019","volume":"Xx Xxxx","author":"Fan","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.xphs.2022.06.004_bib0056","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1128\/jvi.65.2.992-995.1991","article-title":"Chloroquine enhances replication of semliki forest virus and encephalomyocarditis virus in mice","volume":"65","author":"Maheshwari","year":"1991","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.xphs.2022.06.004_bib0057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v10050268","article-title":"Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection","volume":"10","author":"Roques","year":"2018","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.xphs.2022.06.004_bib0058","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4269\/ajtmh.1999.61.180","article-title":"Acceleration of viral replication and up-regulation of cytokine levels by antimalarials: implications in malaria-endemic areas","volume":"61","author":"Seth","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.xphs.2022.06.004_bib0059","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa321","article-title":"Could chloroquine \/hydroxychloroquine be harmful in coronavirus disease 2019 (COVID-19) treatment?","author":"Guastalegname","year":"2020","journal-title":"Clin Infect Dis."},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0060","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1038\/s41467-021-22446-z","article-title":"Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials","volume":"12","author":"Axfors","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.xphs.2022.06.004_bib0061","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 \u2014 interim WHO solidarity trial results","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.xphs.2022.06.004_bib0062","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Japan Acad Ser B"},{"issue":"45","key":"10.1016\/j.xphs.2022.06.004_bib0063","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xphs.2022.06.004_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19\u00a0: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.xphs.2022.06.004_bib0065","article-title":"Favipiravir versus arbidol for COVID-19\u00a0: a randomized clinical trial","author":"Chen","year":"2022","journal-title":"medRxiv preprint"},{"key":"10.1016\/j.xphs.2022.06.004_bib0066","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ijid.2020.11.008","article-title":"Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia","volume":"102","author":"Khamis","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0067","doi-asserted-by":"crossref","first-page":"11022","DOI":"10.1038\/s41598-021-90551-6","article-title":"The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials","volume":"11","author":"Hassanipour","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-021-06164-x","article-title":"Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis","volume":"21","author":"Manabe","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"12","key":"10.1016\/j.xphs.2022.06.004_bib0069","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1007\/s10096-021-04307-1","article-title":"Effectiveness of favipiravir in COVID-19: a live systematic review","volume":"40","author":"\u00d6zl\u00fc\u015fen","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.xphs.2022.06.004_bib0070","unstructured":"Appili Therapeutics. Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan\u00ae\/ReeqonusTM. Accessed January 4, 2022. Published 2021; https:\/\/www.appilitherapeutics.com\/newsfeed\/Appili-Therapeutics-Provides-Update-on-Phase-3-PRESECO-Clinical-Trial-Evaluating-Avigan\u00ae%2FReeqonusTM"},{"key":"10.1016\/j.xphs.2022.06.004_bib0071","series-title":"Molnupiravir, A Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2","author":"Painter","year":"2019"},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0072","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.xphs.2022.06.004_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103595","article-title":"The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model","volume":"72","author":"Abdelnabi","year":"2021","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.xphs.2022.06.004_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2021.102329","article-title":"Molnupiravir in COVID-19: A systematic review of literature","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"10.1016\/j.xphs.2022.06.004_bib0075","series-title":"Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)","author":"ClinicalTrials.gov","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0076","series-title":"Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study","author":"Merck","year":"2022"},{"issue":"3","key":"10.1016\/j.xphs.2022.06.004_bib0077","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3201\/eid1003.030683","article-title":"Coronaviridae and SARS-associated coronavirus strain HSR1","volume":"10","author":"Vicenzi","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"10.1016\/j.xphs.2022.06.004_bib0078","doi-asserted-by":"crossref","first-page":"e23710","DOI":"10.1371\/journal.pone.0023710","article-title":"Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans","volume":"6","author":"Lang","year":"2011","journal-title":"PLoS One"},{"issue":"January","key":"10.1016\/j.xphs.2022.06.004_bib0079","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.antiviral.2016.12.023","article-title":"Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells","volume":"140","author":"Ghezzi","year":"2017","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0080","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/jvi.63.1.52-58.1989","article-title":"Initial interaction of herpes simplex virus with cells is binding to heparan sulfate","volume":"63","author":"WuDunn","year":"1989","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.xphs.2022.06.004_bib0081","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1039\/C4MD00516C","article-title":"Inhibition of influenza H5N1 invasion by modified heparin derivatives","volume":"6","author":"Skidmore","year":"2015","journal-title":"Med Chem Commun"},{"issue":"2","key":"10.1016\/j.xphs.2022.06.004_bib0082","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/glycob\/8.2.131","article-title":"Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor","volume":"8","author":"Harrop","year":"1998","journal-title":"CD4. Glycobiology."},{"issue":"17","key":"10.1016\/j.xphs.2022.06.004_bib0083","doi-asserted-by":"crossref","first-page":"11313","DOI":"10.1074\/jbc.272.17.11313","article-title":"Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size","volume":"272","author":"Rusnati","year":"1997","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.xphs.2022.06.004_bib0084","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.xphs.2022.06.004_bib0085","article-title":"Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin","author":"Mycroft-West","year":"2020","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0086","first-page":"4263","article-title":"Causes of death and comorbidities in hospitalized patients with COVID-19","volume":"11","author":"Elezkurtaj","year":"2021","journal-title":"Nat Sci Reports"},{"issue":"6","key":"10.1016\/j.xphs.2022.06.004_bib0087","first-page":"588","article-title":"Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2022.06.004_bib0088","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1124\/pharmrev.120.000108","article-title":"Inhaled medicines: past, present, and future","volume":"74","author":"Anderson","year":"2022","journal-title":"Pharmacol Rev"},{"issue":"4","key":"10.1016\/j.xphs.2022.06.004_bib0089","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-020-00459-8","article-title":"Remdesivir for treatment of COVID-19: combination of pulmonary and IV administration may offer aditional benefit","volume":"22","author":"Sun","year":"2020","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2022.06.004_bib0090","series-title":"COVID-19 Tedavisinde Kullan\u0131lacak \u0130la\u00e7lara \u0130li\u015fkin Bilgilendirme Favipiravir 200mg Tablet","author":"Republic of Turkey Ministry of Health","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0091","series-title":"COVID-19 Tedavisinde Kullan\u0131lacak \u0130la\u00e7lara \u0130li\u015fkin Bilgilendirme-Lopinavir 200mg\/Ritonavir 50mg Film Tablet","author":"Republic of Turkey Ministry of Health","year":"2022"},{"issue":"4","key":"10.1016\/j.xphs.2022.06.004_bib0092","first-page":"339","article-title":"Pharmacokinetics of lopinavir\/ritonavir crushed versus whole tablets in children","volume":"58","author":"Best","year":"2011","journal-title":"JAIDS"},{"issue":"21","key":"10.1016\/j.xphs.2022.06.004_bib0093","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1111\/bph.15102","article-title":"Lung tissue distribution of drugs as a key factor for COVID-19 treatment","volume":"177","author":"Wang","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"9","key":"10.1016\/j.xphs.2022.06.004_bib0094","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1023\/B:PHAM.0000041457.64638.8d","article-title":"Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans","volume":"21","author":"Kumar","year":"2004","journal-title":"Pharm Res"},{"issue":"1785","key":"10.1016\/j.xphs.2022.06.004_bib0095","first-page":"1","article-title":"Synthesis of [18 F]Favipiravir and biodistribution in C3H\/HeN mice as assessed by positron emission tomography","volume":"9","author":"Bocan","year":"2019","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.xphs.2022.06.004_bib0096","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12111002","article-title":"Development of remdesivir as a dry powder for inhalation by thin film freezing","volume":"12","author":"Sahakijpijarn","year":"2020","journal-title":"Pharmaceutics"},{"issue":"14","key":"10.1016\/j.xphs.2022.06.004_bib0097","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/nnm-2020-0475","article-title":"Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro","volume":"16","author":"Vartak","year":"2021","journal-title":"Nanomedicine"},{"issue":"633","key":"10.1016\/j.xphs.2022.06.004_bib0098","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.abl8282","article-title":"Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection","volume":"14","author":"Vermillion","year":"2022","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0099","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1089\/jamp.2020.1648","article-title":"Inhalable hydroxychloroquine powders for potential treatment of COVID-19","volume":"34","author":"Albariqi","year":"2020","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/cts.12923","article-title":"A strategy to treat COVID-19 disease with targeted delivery of inhalable liposomal hydroxychloroquine: a preclinical pharmacokinetic study","volume":"14","author":"Tai","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.xphs.2022.06.004_bib0101","series-title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers","author":"ClinicalTrials.gov","year":"2022"},{"issue":"2","key":"10.1016\/j.xphs.2022.06.004_bib0102","doi-asserted-by":"crossref","first-page":"AB237","DOI":"10.1016\/j.jaci.2020.12.011","article-title":"Phase 1 randomized placebo-controlled study in healthy adult volunteers to evaluate the safety, tolerability, and pharmacokinetics of orally inhaled aerosolized hydroxychloroquine sulfate \u2013 a potential treatment for COVID-19","volume":"147","author":"Bentur","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.xphs.2022.06.004_bib0103","series-title":"Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers","author":"ClinicalTrials.gov","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0104","first-page":"1","article-title":"Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers","author":"de Reus","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.xphs.2022.06.004_bib0105","series-title":"Development and Validation of \u201cReady-to-Use\u201d Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19","author":"ClinicalTrials.gov","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0106","series-title":"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation","author":"ClinicalTrials.gov","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0107","series-title":"Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 (NEUROSIVIR)","author":"ClinicalTrials.gov","year":"2022"},{"issue":"7","key":"10.1016\/j.xphs.2022.06.004_bib0108","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.burns.2011.07.006","article-title":"Safety and potential anticoagulant effects of nebulised heparin in burns patients with inhalational injury at Singapore General Hospital Burns Centre","volume":"37","author":"Yip","year":"2011","journal-title":"Burns"},{"issue":"3","key":"10.1016\/j.xphs.2022.06.004_bib0109","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/jamp.2009.0780","article-title":"Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis","volume":"23","author":"Markart","year":"2010","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"2","key":"10.1016\/j.xphs.2022.06.004_bib0110","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jconrel.2012.07.008","article-title":"Inhaled extended-release microparticles of heparin elicit improved pulmonary pharmacodynamics against antigen-mediated airway hyper-reactivity and inflammation","volume":"162","author":"Yildiz","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.xphs.2022.06.004_bib0111","first-page":"1","article-title":"Low molecular weight heparin nebulization attenuates acute lung injury","volume":"2017","author":"Xie","year":"2017","journal-title":"Biomed Res Int"},{"issue":"Pt 2","key":"10.1016\/j.xphs.2022.06.004_bib0112","first-page":"603","article-title":"Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects","volume":"58","author":"Scheuch","year":"2007","journal-title":"J Physiol Pharmacol"},{"issue":"5 I","key":"10.1016\/j.xphs.2022.06.004_bib0113","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1164\/ajrccm.160.5.9809123","article-title":"Lung deposition and clearance of inhaled 99mTc-heparin in healthy volunteers","volume":"160","author":"Bendstrup","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.xphs.2022.06.004_bib0114","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1160\/TH17-05-0347","article-title":"Nebulized heparin attenuates pulmonary coagulopathy and inflammation through alveolar macrophages in a rat model of acute lung injury","volume":"117","author":"Chimenti","year":"2017","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.xphs.2022.06.004_bib0115","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/CCM.0b013e3182a645e5","article-title":"Inhaled anticoagulation regimens for the treatment of smoke inhalation\u2013associated acute lung injury","volume":"42","author":"Miller","year":"2014","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.xphs.2022.06.004_bib0116","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/00004630-199805000-00004","article-title":"Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin\/acetylcystine therapy","volume":"19","author":"Desai","year":"1998","journal-title":"J Burn Care Rehabilition"},{"issue":"2","key":"10.1016\/j.xphs.2022.06.004_bib0117","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/BCR.0b013e318198a268","article-title":"Influence of nebulized unfractionated heparin and n-acetylcysteine in acute lung injury after smoke inhalation injury","volume":"30","author":"Miller","year":"2009","journal-title":"J Burn Care Res"},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0118","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/BCR.0000000000000439","article-title":"Outcomes following the use of nebulized heparin for inhalation injury (HIHI Study)","volume":"38","author":"McIntire","year":"2017","journal-title":"J Burn Care Res"},{"issue":"4","key":"10.1016\/j.xphs.2022.06.004_bib0119","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-2600(20)30470-7","article-title":"Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"9","author":"Dixon","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"1-3","key":"10.1016\/j.xphs.2022.06.004_bib0120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejphar.2004.11.014","article-title":"Effects of bemiparin on airway responses to antigen in sensitized Brown\u2013Norway rats","volume":"507","author":"Suchankova","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"454","key":"10.1016\/j.xphs.2022.06.004_bib0121","first-page":"1","article-title":"Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence","volume":"24","author":"van Haren","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.xphs.2022.06.004_bib0122","series-title":"Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19 (NEBUHEPA)","author":"ClinicalTrials.gov","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0123","series-title":"Nebulized Heparin for the Treatment of COVID-19 (INHALE-HEP)","author":"ClinicalTrials.gov","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0124","series-title":"Inhaled Heparin for Hospitalised COVID-19 Patients (INHALE-HEP)","author":"ClinicalTrials.gov","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0125","series-title":"Nebulized Heparin for COVID19-associated Acute Respiratory Failure","author":"ClinicalTrials.gov","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0126","series-title":"Nebulised Heparin in Patients With Severe COVID-19 (CHARTER-MT)","author":"ClinicalTrials.gov","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0127","series-title":"Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury","author":"ClinicalTrials.gov","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0128","series-title":"Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia","author":"ClinicalTrials.gov","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0129","series-title":"Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury (CHARTER-Irl)","author":"ClinicalTrials.gov","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0130","first-page":"1","article-title":"INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studies","author":"van Haren","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2022.06.004_bib0131","first-page":"1","article-title":"Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients","volume":"2022","author":"van Haren","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"1768","key":"10.1016\/j.xphs.2022.06.004_bib0132","first-page":"1","article-title":"Early effects of low molecular weight heparin therapy with soft-mist inhaler for covid-19-induced hypoxemia\u00a0: a phase iib trial","volume":"13","author":"Erelel","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2022.06.004_bib0133","series-title":"Concepts and Principles of Pharmacology-100 Years of the Handbook of Experimental Pharmacology","article-title":"100 Years of drug delivery to the lungs-","author":"Lavorini","year":"2019"},{"key":"10.1016\/j.xphs.2022.06.004_bib0134","series-title":"Modified-Release Drug Delivery Technology","first-page":"807","article-title":"Pulmonary delivery of drugs by inhalation","author":"Gonda","year":"2002"},{"issue":"5","key":"10.1016\/j.xphs.2022.06.004_bib0135","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/17425247.2020.1739021","article-title":"Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease","volume":"17","author":"Cazzola","year":"2020","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"10.1016\/j.xphs.2022.06.004_bib0136","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1590\/1984-0462\/;2018;36;3;00002","article-title":"Comparison of two inhalational techniques for bronchodilator administration in children and adolescents with acute asthma crisis: a meta\u2011analysis","volume":"36","author":"Roncada","year":"2018","journal-title":"Rev Paul Pediatr"},{"issue":"7","key":"10.1016\/j.xphs.2022.06.004_bib0137","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s40267-020-00740-y","article-title":"Amid COVID-19 drug shortages: proposed plan for reprocessing and reusing salbutamol pressurized metered dose inhalers (pMDIs) for shared use","volume":"36","author":"Elbeddini","year":"2020","journal-title":"Drugs Ther Perspect"},{"issue":"4","key":"10.1016\/j.xphs.2022.06.004_bib0138","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/17425247.2016.1224846","article-title":"Dry powder inhalation: past, present and future","volume":"14","author":"de Boer","year":"2017","journal-title":"Expert Opin Drug Deliv"},{"issue":"10","key":"10.1016\/j.xphs.2022.06.004_bib0139","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s12325-019-01066-6","article-title":"Understanding dry powder inhalers: key technical and patient preference attributes","volume":"36","author":"Levy","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.xphs.2022.06.004_bib0140","first-page":"34","article-title":"Enhancing the performance of dry powder inhalers: breath actuated mechanisms","volume":"66","author":"Tweedie","year":"2016","journal-title":"ONdrugDelivery Mag"},{"issue":"6","key":"10.1016\/j.xphs.2022.06.004_bib0141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/prp2.675","article-title":"Climate change in healthcare: Exploring the potential role of inhaler prescribing","volume":"8","author":"Starup-Hansen","year":"2020","journal-title":"Pharmacol Res Perspect"},{"issue":"6","key":"10.1016\/j.xphs.2022.06.004_bib0142","first-page":"609","article-title":"Nebulizers\u00a0: principles and performance nebulizers\u00a0: principles and performance","volume":"45","author":"Hess","year":"2000","journal-title":"Respir Care"},{"issue":"1","key":"10.1016\/j.xphs.2022.06.004_bib0143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5152\/ejp.2014.00087","article-title":"Jet, ultrasonic, and mesh nebulizers: an evaluation of nebulizers for better clinical outcomes","volume":"16","author":"Ari","year":"2014","journal-title":"Eurasian J Pulmonol"},{"issue":"7","key":"10.1016\/j.xphs.2022.06.004_bib0144","first-page":"845","article-title":"Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation","volume":"55","author":"Ari","year":"2010","journal-title":"Respir Care"},{"issue":"1-2","key":"10.1016\/j.xphs.2022.06.004_bib0145","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijpharm.2011.01.024","article-title":"Deposition of aerosols delivered by nasal route with jet and mesh nebulizers","volume":"407","author":"Vecellio","year":"2011","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2022.06.004_bib0146","first-page":"174","article-title":"Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric","volume":"49","author":"Rau","year":"2004","journal-title":"Respir Care"},{"issue":"4","key":"10.1016\/j.xphs.2022.06.004_bib0147","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/jamp.2014.1149","article-title":"Performance comparisons of jet and mesh nebulizers using different interfaces in simulated spontaneously breathing adults and children","volume":"28","author":"Ari","year":"2015","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"April","key":"10.1016\/j.xphs.2022.06.004_bib0148","article-title":"Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19","volume":"167","author":"Ari","year":"2020","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.xphs.2022.06.004_bib0149","first-page":"160","article-title":"Aerosolization of COVID-19 and contamination risks during respiratory treatments","volume":"37","author":"Benge","year":"2020","journal-title":"Fed Pract"},{"key":"10.1016\/j.xphs.2022.06.004_bib0150","series-title":"COVID-19: Management in Hospitalized Adults","author":"Kim","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0151","article-title":"Prevention and control of influenza during a pandemic for all healthcare settings","year":"2011","journal-title":"Can Pandemic Influ Plan Heal Sect"},{"key":"10.1016\/j.xphs.2022.06.004_bib0152","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s41030-017-0040-8","article-title":"The Respimat\u00ae Development story: patient-centered innovation","volume":"3","author":"Wachtel","year":"2017","journal-title":"Pulm Ther"},{"issue":"11","key":"10.1016\/j.xphs.2022.06.004_bib0153","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40261-019-00835-z","article-title":"The Respimat\u00ae Soft mist inhaler: implications of drug delivery characteristics for patients","volume":"39","author":"Iwanaga","year":"2019","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.xphs.2022.06.004_bib0154","first-page":"145","article-title":"Development of Respimat® Soft Mist™ Inhaler and its clinical utility in respiratory disorders","volume":"4","author":"Dalby","year":"2011","journal-title":"Med Devices Evid Res"},{"issue":"4","key":"10.1016\/j.xphs.2022.06.004_bib0155","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1378\/chest.113.4.957","article-title":"Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines * Comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices","volume":"113","author":"Newman","year":"1998","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.xphs.2022.06.004_bib0156","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1089\/jam.2005.18.264","article-title":"Deposition of Corticosteroid aerosol in the human lung by Respimat\u00ae Soft MistTM inhaler compared to deposition by metered dose inhaler or by Turbuhaler\u00ae Dry powder inhaler","volume":"18","author":"Pitcairn","year":"2005","journal-title":"J Aerosol Med"},{"issue":"3-4","key":"10.1016\/j.xphs.2022.06.004_bib0157","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ddstr.2011.07.001","article-title":"Formulation technology to repurpose drugs for inhalation delivery","volume":"8","author":"Cipolla","year":"2011","journal-title":"Drug Discov Today Ther Strateg"},{"issue":"5","key":"10.1016\/j.xphs.2022.06.004_bib0158","doi-asserted-by":"crossref","first-page":"667","DOI":"10.4155\/tde.10.54","article-title":"Personalizing aerosol medicine: development of delivery systems tailored to the individual","volume":"1","author":"Cipolla","year":"2010","journal-title":"Ther Deliv"},{"key":"10.1016\/j.xphs.2022.06.004_bib0159","series-title":"Compositions Comprising an RNA Polymerase Inhibitor and Cyclodextrin for Treating Viral Infections","author":"Larson","year":"2019"},{"key":"10.1016\/j.xphs.2022.06.004_bib0160","series-title":"Cyclodextrins Used as Excipients.; 2017","author":"European Medicines Agency","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0161","series-title":"Inactive Ingredient Search for Approved Drug Products","author":"US Food and Drug Administration","year":"2022"},{"key":"10.1016\/j.xphs.2022.06.004_bib0162","first-page":"143","article-title":"Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19","author":"Kavanagh","year":"2020","journal-title":"Med Hypotheses"},{"issue":"21","key":"10.1016\/j.xphs.2022.06.004_bib0163","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1111\/bph.15167","article-title":"Novel approach for low-dose pulmonary delivery of hydroxychloroquine in COVID-19","volume":"177","author":"Fassihi","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.xphs.2022.06.004_bib0164","first-page":"142","article-title":"Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection","author":"Klimke","year":"2020","journal-title":"Med Hypotheses"},{"issue":"2","key":"10.1016\/j.xphs.2022.06.004_bib0165","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/00498254.2020.1824301","article-title":"Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients\u2019 characteristics: a review of the literature and simulations","volume":"51","author":"Karatza","year":"2021","journal-title":"Xenobiotica"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922002489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922002489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:38:41Z","timestamp":1758361121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354922002489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":165,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0022354922002489"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2022.06.004","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2022.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}